- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2024
- 200 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- October 2023
- 183 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- January 2023
- 315 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- August 2022
- 214 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- June 2019
- 130 Pages
United States
€2891EUR$2,995USD£2,480GBP
- Book
- December 2020
Global
- Book
- October 2023
North America
- Book
- July 2021
North America
- Book
- June 2019
North America
The B Cell market within the context of Oncology is a rapidly growing field of research and development. B Cells are a type of white blood cell that play a key role in the body's immune system. In oncology, B Cells are used to target and destroy cancer cells. B Cell therapies are a type of immunotherapy, which is a form of cancer treatment that uses the body's own immune system to fight the disease. B Cell therapies are being developed to target a variety of cancers, including lymphoma, leukemia, and multiple myeloma.
B Cell therapies are being developed by a number of companies, including Kite Pharma, Juno Therapeutics, and Bluebird Bio. These companies are working to develop treatments that are more effective and have fewer side effects than traditional chemotherapy and radiation treatments. Additionally, these companies are researching ways to use B Cells to target and destroy cancer cells without damaging healthy cells. Show Less Read more